Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Scandiatransplant acceptable mismatch program (STAMP) a bridge to transplanting highly immunized patients

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Identification of the novel HLA allele, HLA-C*07:780, identified in a Danish woman

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Extended HLA-G haplotypes in patients with age-related macular degeneration

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Obituary

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Identification of the novel HLA allele, HLA-C*07:780, identified in a Danish woman

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. "Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation"

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • P Koefoed-Nielsen
  • I Weinreich
  • M Bengtsson
  • J Lauronen
  • C Naper
  • M Gäbel
  • S S Sørensen
  • L Wennberg
  • A V Reisaeter
  • B K Møller
  • Nordic Kidney group and the Tissue Typing group in Scandiatransplant
View graph of relations

BACKGROUND: Highly immunized patients are a challenge for organ transplantation programs. One way of increasing the likelihood of transplantation in this group of patients is to expand the possible donations by defining acceptable HLA mismatches. In the Scandiatransplant Acceptable Mismatch Program (STAMP), a de-centralized approach has been implemented in 2009.

AIMS: The program has been improved during the years from utilizing HLA-A, -B, -DR matching only to include typing of all deceased donors for HLA-A, -B, -C, -DRB1 and -DQB1. The calculation of a transplantability score (TS) has been introduced in order to take both HLA and AB0 into consideration resulting in a more realistic picture of the transplantability chance.

MATERIALS AND METHODS: Patients were selected for eligibility and results of immunisation status were prepared in each of the 9 tissue typing laboratories, while access to the program is finally governed by a common steering group of immunologists and clinicians.

RESULTS: In the period from March 2009 until February 2015, 96 patients were transplanted within this program. The mean recipient age was 49 years and 57% were females, 30% of the patients were first transplants and of these 93% were females. The majority of the patients had 2-5 HLA-A, -B. -DR mismatches. The allograft survival at 60 months was 79.1%. Applying the TS to the cohort confirmed that patients with a low TS score had longer waiting times.

CONCLUSION: The program has matured during the years and now proves to be a valid approach for transplanting highly immunized patients.

Original languageEnglish
JournalHLA
Volume90
Issue number1
Pages (from-to)17-24
Number of pages8
ISSN2059-2302
DOIs
Publication statusPublished - Jul 2017

    Research areas

  • Journal Article

ID: 52632857